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in a series of controlled clinical trials.11,12
The therapeutic index of HDC requiring the sup-
port of autologous HSC transplantation is mainly
dependent on the number of transplanted CD34+
cells. In the autologous transplantation setting, the
dose of reinfused HSC measured by the CD34+ cell
assay13 is an accurate predictor of the kinetics of
reconstitution of marrow function following the
inevitable drug-induced pancytopenia.14 A dose
greater than 53106 CD34+ cells per kg of body weight
is recommended because this dose is associated with
significantly more rapid and complete reconstitution
of marrow functions than lower doses. This effect
implies the reduction or abrogation of transfusion
requirements, extra-hematopoietic toxicity, sup-
portive care, duration of hospital stay, and overall
treatment costs.15,16 In addition, optimal hematopoi-
etic reconstitution after transplantation allows ear-
ly curative surgery and the delivery of boost radiation
therapy for locally advanced BC and further chemo-
therapy for metastatic BC. In view of cell therapy,
the availability of large numbers of HSC facilitates
the application of ex-vivo manipulation and purifica-
tion aimed at removing undesired tumor cells.17
In the present issue of Haematologica, Zibera et al.18
report on the possibility of harvesting large amounts
of progenitor cells following epirubicin/paclitaxel (EP)
combination plus G-CSF in 25 patients with stage IV
BC. The authors document that the tempo for circu-
lating progenitor cell collection is highly predictable
(day 10 to day 12 following combination chemother-
apy) and in most of patients a single leukapheresis is
sufficient for optimal CD34+ cell yield. The authors
accomplished this result by carrying out leukaphere-
ses in patients with >30 CD34+ cell per mL. Based on
data recently published in Haematologica,19 it is
expected that even better results could be achieved
by adopting modern technology of leukapheresis that
allows harvesting of the target dose of 53106 CD34+
cells per kg by a single leukapheresis also in patients
with lower blood CD34+ cell counts.19 In the study by
Zibera et al., mobilization and harvesting was per-
formed in patients showing response to three cycles
of chemotherapy with EP. In this regards, it is rele-
vant that the EP regimen does not hamper either the
mobilization capacity of patients after three cycles of
therapy or the quality of the HSC, the latter measured
by the LTC-IC count in the leukapheresis products.
Consequently, oncologists have the opportunity to
give three courses of anticancer therapy, evaluate the
tumor response, and decide whether or not to harvest
HSC for a subsequent HDC approach.
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Breast cancer (BC) is the most common malignan-
cy among women in the Western world and is the
leading cause of cancer death among European
women.1 For locally advanced and metastatic disease
the indication for high dose chemotherapy (HDC)
with hematopoietic stem cell (HSC) support is still
controversial mainly because of the lack of large ran-
domized trials.2,3 Nevertheless, the wide utilization of
HDC with HSC support for BC as documented by reg-
istries of the EBMT and IBMTR4-6 is based on the
encouraging results of phase II and III studies show-
ing an increase in disease-free and overall survival, and
suggesting that this approach may be curative in a
small subset of patients with stage IV disease.6-8 Inter-
estingly, there is strong evidence that the efficacy of
HDC with HSC support for BC is mainly dependent
on the possibility of treating women with chemosen-
sitive neoplasms who have shown a response to con-
ventional chemotherapy regimens.6 In this scenario
one may hypothesize that the ideal first-line regimen
for patients with locally advanced or metastatic (stage
IIIB and stage IV) BC should have potent anticancer
effect measured by the highest rate of induction of
tumor regression, as well as potent ability to mobilize
hematopoietic stem cells into peripheral blood mea-
sured by the highest yield of CD34+ cells in a single
leukapheresis collection.
It is well documented that anticancer chemothera-
py with a combination of an anthracycline, e.g. doxo-
rubicin or epirubicin, and a taxane, e.g. docetaxel or
paclitaxel, meets the first requirement. Although
tumor cell resistance to taxanes and to anthracyclines
shares the same pleiotropic mechanisms, in the clin-
ical setting the combination of either drug of these
classes results in unprecedented response rates in
chemotherapy-naive women with BC.9 Furthermore,
approximately 20-40% of patients failing to respond
to first-line anthracycline treatment do benefit from
second-line therapy with a taxane.10 In most treated
patients, iatrogenic toxicity to the hematopoietic sys-
tem is usually treatable with commercially available
hematopoietic growth factors. Because of these
pieces of evidence, the association of a taxane with an
anthracycline has now become the first treatment
option for selected patients with advanced BC and
its efficacy in an adjuvant setting is also being explored
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Despite advances in HDC with autologous HSC
transplantation for hematologic malignancies and sol-
id tumors, relapse of the underlying disease remains a
major obstacle which has yet to be overcome. Future
developments of anticancer therapy may rely on the
exploitation of HSC beyond their use as hematopoietic
support. Recent advances in tumor vaccine develop-
ment, specifically, the molecular identification of nov-
el tumor antigens and the understanding of cellular
signals delivered by cytokines and co-stimulatory mol-
ecules required for efficient T-cell activation, now
make it possible to consider combining active specif-
ic immunotherapy with HSC transplantation as a
strategy for elimination of residual tumor following
intensive primary chemotherapy. A powerful means of
inducing both cellular and humoral immunity is the
expression of antigen-encoding DNA sequences in
host antigen presenting cells (APC). Dendritic cells are
among the most potent APC described and it is now
possible to prepare large numbers of DCs from human
circulating CD34+ hematopoietic progenitors.20 This
has led to an explosion in DC research as well as the
potential to treat patients with therapeutic doses of
autologous DCs. Various BC-associated antigens,
including HER-2/neu, CEA, MAGE-1, p53, and MUC-
1 appear to be ideal targets for immunotherapy and
are currently under investigation in humans.21,22 Prim-
itive hematopoietic progenitors are also attractive tar-
gets for gene therapy because of their potential to self-
renew and generate a large population of progeny cells
with new genetic material. The potential use of gene-
modified HSC has already branched out into several
directions, as it has been applied in cancer therapy.
First, the introduction of HSC modified with a drug
resistance gene is being investigated as a means to
select those cells that express the introduced drug
resistance gene and to protect the infused bone mar-
row cells from destruction by repeated chemotherapy
treatments.23 An additional strategy may be the use of
this drug-resistance selection to increase the frequen-
cy of gene-modified cells that also contain a thera-
peutic transgene with antitumor activity.24 Finally,
HSC have been proposed as targets for the introduc-
tion of chimeric receptor gene(s) with reactivity to
tumor-associated antigens, which would potentially
offer the patient receiving a gene-modified HSC trans-
plant a long-term antitumor immune response that is
biased to recognize autologous tumor.25,26
In conclusion, we welcome the study by Zibera et al.
as a well documented guideline for treating BC with the
potent taxane-anthracycline regimen while also taking
advantage of the availability of copious HSC mobilized
into peripheral blood, these cells being potentially use-
ful tools for further innovative therapies.
Salvatore Siena
Divisione di Oncologia Medica Falck, 
Ospedale Niguarda Ca’ Granda,
piazza Ospedale Maggiore 3, 20162 Milan, Italy.
E-mail: salsiena@tin.it
References
1. Moller-Jensen O, Esteve J, Moller H, Renard H. Cancer
in the European Community and its member states.
Eur J Cancer 1990; 26:1167-256.
2. Hortobagyi GN. Treatment of breast cancer. N Engl J
Med 1998; 339:974-84.
3. Crown J. High dose chemotherapy of metastatic breast
cancer: the end of the beginning. Br J Cancer 1997;
75:467-9.
4. Anonymous. Chaos surrounds high-dose chemothera-
py for breast cancer. Lancet 1999; 353:1633.
5. Gratwhol A, Passweg J, Baldomero H, Hermans J.
Blood and marrow transplantation activity in Europe
1997. Bone Marrow Transplant 1999; 24:231-45.
6. Antman KH, Rowlings PA, Vaughan WP, et al. High-
dose chemotherapy with autologous hematopoietic
stem-cell support for breast cancer in north America. J
Clin Oncol 1997; 15:1870-9.
7. Bezwoda WR, Seymour L, Dansey RD. High-dose
chemotherapy with hematopoietic rescue as primary
treatment for metastatic breast cancer: a randomized
trial. J Clin Oncol 1995; 13: 2483-9.
8. Adkins D, Brown R, Trinkaus K, et al. Outcomes of
high-dose chemotherapy and autologous stem cell
transplantation in stage IIIB inflammatory breast can-
cer, J Clin Oncol 1999; 17: 2006-14.
9. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-
hour infusion in combination with bolus doxorubicin in
women with untreated metastatic breast cancer: high
antitumor efficacy and cardiac effects in a dose-finding
and sequence-finding study. J Clin Oncol 1995;
13:2688-99.
10. Gianni L, Munzone E, Capri G, et al. Paclitaxel in
metastatic breast cancer: a trial of two doses by 3-hour
infusion in patients with disease recurrence after prior
therapy with anthracyclines. J Natl Cancer Inst 1995;
87:1169-75.
11. Goldspiel BR. Clinical overview of the taxanes. Phar-
macotherapy 1997; 17:110S-125S. 
12. Esteva FJ, Hortobagyi GN. Integration of systemic
chemotherapy in the management of primary breast
cancer. The Oncologist 1998; 3:300-13.
13. Siena S, Bregni M, Brando B et al. Flow cytometry for
clinical estimation of circulating hematopoietic prog-
enitors for autologous transplantation in cancer
patients. Blood 1991; 77:400-9.
14. Bensinger W, Appelbaum F, Rowley S, et al. Factors
that influence collection and engraftment of autolo-
gous peripheral-blood stem cells. J Clin Oncol 1995;
13:2547-55.
15. Schmitz N, Linch DC, Dreger P, et al. Randomized tri-
al of filgrastim-mobilized peripheral blood progenitor
cell transplantation versus autologous bone-marrow
transplantation in lymphoma patients. Lancet 1996;
347:353-7.
16. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH.
Effect of CD34+ cell dose on resource utilization in
patients after high dose chemotherapy with peripheral
blood stem cell support. J Clin Oncol 1999; 17: 1227-
33.
17. Spyridinidis A, Schmid M, Bernhardt  W, et al. Purging
of mammary carcinoma cells during ex vivo culture of
CD34+ hematopoietic progenitor cells with recombi-
nant immunotoxins. Blood 1998; 91:1820-7.
18. Zibera C, Pedrazzoli P, Ponchio L, et al. Efficacy of
epirubicin/paclitaxel combination in mobilizing large
amounts of hematopoietic progenitor cells in patients
with metastatic breast cancer showing optimal
response to the same chemotherapy regimen. Haema-
tologica 1999; 84:924-9.
Editorials866
Haematologica vol. 84(10):October 1999
19. Granzow K, Schiavo R, Timofeeva I, Moroni G, San-
toro A, Siena S. New technology and changing para-
meters of leukapheresis for blood cell transplantation.
Haematologica 1999; 84:752-3.
20. Siena S, Di Nicola M, Bregni M, et al. Massive ex vivo
generation of functional dendritic cells from mobilized
CD34+ blood progenitors for anticancer therapy. Exp
Hematol 1995; 23:1463-71.
21. Hadden JW. The immunology and immunotherapy of
breast cancer: an update. Int J Immunopharmacol
1999; 21:79-101.
22. Di Nicola M, Siena S, Bregni M. Gene transfer into
human dendritic antigen-presenting cells by vaccinia
virus and adenovirus vectors. Cancer Gene Ther 1998;
5:350-6.
23. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of
retroviral-mediated transfer of the human MDR1 gene
as marrow chemoprotection in patients undergoing
high-dose chemotherapy and autologous stem-cell
transplantation. J Clin Oncol 1998;16:165-72. 
24. Koc ON, Davis BM, Reese JS, Friebert SE, Gerson S.
Transfer of drug resistance genes into hematopoietic
progenitors. In: Lattime EC, Gerson SL, eds. Gene ther-
apy of cancer. London: Academic Press, 1999, p. 177-
200.
25. Wilke LG, Reynolds CM, McDonagh KT, et al. Engi-
neering immune effector cells to target the Her2/neu
breast cancer antigen. SSO Annual Cancer Symposium
1997; 51:P4.
26. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian
cancer cells by human lymphocytes redirected with a
chimeric gene composed of an antibody variable region
of the Fc receptor g chain. J Exp Med 1993; 178:361-
6.
Drawbacks of serum transferrin
receptor as a diagnostic tool
In this issue Mockenhaupt et al.1 report on interest-
ing studies performed in Nigeria to evaluate the use-
fulness of serum transferrin receptor as a diagnostic
tool for iron deficiency. The soluble transferrin recep-
tor is a tool for both the quantitative determination of
marrow erythropoietic activity and the diagnosis of
iron deficiency. Previous papers in this journal have
described various clinical applications of such a diag-
nostic tool.2-9 More recently, two studies have evalu-
ated the diagnostic efficiency of the soluble transfer-
rin receptor assay in the diagnosis of iron depletion in
patients with anemia of chronic disorders, providing
partially conflicting results.8,9 In conclusion: a) the sol-
uble transferrin receptor level is influenced by the ery-
throid marrow activity (and therefore by congenital
and acquired erythroid disorders); b) this assay might
not assess the iron status of patients with anemia of
chronic diseases accurately; c) the available kits are
expensive. Based on these considerations, it is unlike-
ly that serum transferrin receptor may be largely
employed as a diagnostic or screening tool in Africa.
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Towards identification of subsets
of patients with multiple myeloma
who benefit from high-dose
chemotherapy
Haematologica has recently published a review arti-
cle on treatment of multiple myeloma,1 an analysis of
optimization of peripheral blood progenitor cell autol-
ogous transplantation in this condition2 and the GIT-
MO experience in this field.3 Previous papers dealt with
treatment of multiple myeloma.4-9
In this issue, Boccadoro et al.10 report on a study
comparing high-dose vs conventional chemothera-
py. Their findings strongly suggest the superiority of
high-dose chemotherapy for multiple myeloma
patients below 55, at least in terms of complete
remission and event-free survival. Although this
observation needs to be confirmed by other inde-
pendent studies, it represents a step forward towards
identification of subsets of patients who would be
best candidates for high-dose chemotherapy.
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